Analgesic Effectiveness of PENG Block in Programmed Hip Arthroplasty Surgery (THAPeng)

November 21, 2025 updated by: University Hospital, Toulouse

The intra- and peri-articular infiltration of local anaesthetics realized at the end of total hip arthroplasty surgeries is an effective analgesic technique, but it can be insufficient to manage the possibly intense postoperative pain. Regional anaesthesia (RA) like the recently described pericapsular nerve group (PENG) block could provide additional analgesic benefit in this setting.

Investigators main objective is to demonstrate the analgesic benefits (postoperative pain score and morphine consumption) of the PENG block when added to intra- and peri-articular infiltration of local anaesthetic following total hip arthroplasty. Investigators make the assumption that i) the PENG bloc could reduce the postoperative 24 first hours morphine consumption by 30%, ii) the PENG block could spare the motor function of the quadriceps and adductor muscles, and iii) the PENG bloc could be well tolerated allowing a high level of patient satisfaction.

Study Overview

Detailed Description

A recent study has revealed a region of pericapsular terminal branches of the femoral nerve and the obturator nerve accessible to ultrasound-guided regional anaesthesia. This technique, also called the PENG block, has recently been described with a substantial benefit on pain at rest and induced by mobilization in cases series of patients undergoing hip fracture surgery. To investigators knowledge, no randomized data concerning the analgesic efficacy of the PENG block has been published in the setting of elective total hip arthroplasty.

The PENG block would allow a significant analgesic contribution when added to intra- and peri-articular infiltration of local anaesthetics while being well tolerated with few undesirable effects. Moreover, the PENG block could spare the motor function of the quadriceps and adductor muscles allowing enhanced recovery after surgery

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Toulouse, France
        • University Hospital of Toulouse

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Scheduled for total hip arthroplasty surgery under general anaesthesia
  • Affiliated of a social security scheme
  • Having signed the written informed consent

Exclusion Criteria:

  • Total hip arthroplasty revision surgery
  • Refusal of the patient to participate
  • Existence of major spontaneous or acquired haemostasis disorders
  • Infection at the puncture site
  • Allergy to local anaesthetics
  • Pregnancy or breast-feeding
  • Patients under the protection of adults (guardianship, curatorship or protection of justice)
  • Patients whose cognitive state does not allow assessment by the scales used.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PENG group
For the PENG group, the ultrasound-guided PENG block (20 ml of Ropivacaine 4.75 mg/ml) is performed before the surgery.
ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
No Intervention: Control group
No additional intervention, only standard care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulated postoperative morphine consumption 24 hours after surgery
Time Frame: 24 hours
calcul of Cumulated postoperative morphine consumption 24 hours after surgery
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulated postoperative morphine consumption in the post anaesthesia care unit (PACU)
Time Frame: Hour 1
Cumulated postoperative morphine consumption in the post anaesthesia care unit (PACU)
Hour 1
Cumulated postoperative morphine consumption 48 hours after surgery
Time Frame: Hour 48
Cumulated postoperative morphine consumption 48 hours after surgery
Hour 48
Evaluation of pain in the PACU
Time Frame: Hour 1
Evaluation of pain using a simple numeric rating scale (NRS from 0 to 10) in the PACU
Hour 1
Evaluation of pain 24 hours after surgery
Time Frame: Hour 24
Evaluation of pain using a simple numeric rating scale (NRS from 0 to 10) 24 hours after surgery
Hour 24
Evaluation of pain 48 hours after surgery
Time Frame: Hour 48
Evaluation of pain using a simple numeric rating scale (NRS from 0 to 10) 48 hours after surgery
Hour 48
Evaluation of the pain potentially induced by the realization of the PENG block
Time Frame: Hour 0
Evaluation of the pain potentially induced by the realization of the PENG block with Likert scale from 1 to 5, 1 is for no pain, 5 is for the worse pain
Hour 0
Evaluation of adverse effects associated with the PENG block
Time Frame: Hour 0
Evaluation of adverse effects associated with the PENG block
Hour 0
Evaluation of adverse effects associated with the PENG block
Time Frame: Hour 1
Evaluation of adverse effects associated with the PENG block
Hour 1
Evaluation of adverse effects associated with the PENG block
Time Frame: Hour 24
Evaluation of adverse effects associated with the PENG block
Hour 24
Evaluation of adverse effects associated with the PENG block
Time Frame: Hour 48
Evaluation of adverse effects associated with the PENG block
Hour 48
Evaluation of adverse effects associated with the use of morphine
Time Frame: Hour 0
Evaluation of adverse effects associated with the use of morphine
Hour 0
Evaluation of adverse effects associated with the use of morphine
Time Frame: Hour 1
Evaluation of adverse effects associated with the use of morphine
Hour 1
Evaluation of adverse effects associated with the use of morphine
Time Frame: Hour 24
Evaluation of adverse effects associated with the use of morphine
Hour 24
Evaluation of adverse effects associated with the use of morphine
Time Frame: Hour 48
Evaluation of adverse effects associated with the use of morphine
Hour 48
Evaluation of the patients' satisfaction
Time Frame: Hour 24
Evaluation of the patients' satisfaction by the EVAN-LR score realized 24 hours after surgery. EVAN-LR is a scale assessing perioperative patient's satisfaction with Loco Regional anaesthesia
Hour 24
Evaluation of the adductor muscles weakness
Time Frame: Hour 24
Evaluation of the adductor muscles weakness by a thigh adduction test performed 24 hours after surgery
Hour 24
Evaluation of the quadricipital muscles weakness
Time Frame: Hour 24
Evaluation of the quadricipital muscles weakness by a Timed to Up and Go Test performed 24 hours after surgery
Hour 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: FERRE Fabrice, PH, University Hospital, Toulouse

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 14, 2020

Primary Completion (Actual)

July 8, 2021

Study Completion (Actual)

July 8, 2021

Study Registration Dates

First Submitted

November 24, 2020

First Submitted That Met QC Criteria

November 24, 2020

First Posted (Actual)

December 2, 2020

Study Record Updates

Last Update Posted (Actual)

November 28, 2025

Last Update Submitted That Met QC Criteria

November 21, 2025

Last Verified

July 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Pain

Clinical Trials on ultrasound-guided PENG bloc realized before surgery

Subscribe